Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Visceral fat predicts NAFLD fibrosis, progression in HIV

Publish date:: March 26, 2020

Key clinical point: Increased visceral fat predicts both the presence of hepatic fibrosis in HIV patients with nonalcoholic fatty liver disease and its progression.

Major finding: For every 25 cm² rise in baseline visceral fat, the team found a 40% increased odds of fibrosis progression (P = .03).

Study details: Liver biopsies in 58 people with NAFLD and HIV

Disclosures: The work was funded by the National Institutes of Health. The study lead is a paid consultant to Theratechnologies, maker of tesamorelin, a drug to reduce visceral fat in HIV.

Citation:

Fourman LT et al. CROI 2020, Abstract 128.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Infectious Diseases

Obesity, hypoxia predict severity in children with COVID-19,

Prophylactic HIV treatment in female STI patients is rare,

Combo DAA treatments may benefit patients with resistant HCV genotype 3,

Pronounced racial differences in HBsAg loss after stopping nucleos(t)ide,

Opt-out policy at a syringe service program increased HIV/HCV testing,